STOMP Study: Effective Selinexor Regimen in Multitherapy Combo
Noa Biran, MD, delves into the phase II STOMP study, highlighting selinexor’s efficacy with various backbones like pomalidomide, carfilzomib, daratumumab, and reviews dosing strategies and proactive management of associated toxicities.
Video Player is loading.
EP: 1.Addressing Unmet Needs in Relapsed/Refractory Multiple Myeloma
EP: 2.Breakthrough Agents Reshaping RRMM Treatment Landscape
EP: 3.Overview of the BOSTON Trial Evaluating a Selinexor Triplet Regimen
EP: 4.Examining Selinexor Role in RRMM Treatment
Now Viewing
EP: 5.STOMP Study: Effective Selinexor Regimen in Multitherapy Combo
EP: 6.Sequencing Selinexor With Novel BCMA Therapies
EP: 7.Multiple Myeloma: Evolving Therapies and Patient Well-Being
EP: 8.Optimizing Novel Treatment Options in Relapsed/Refractory Multiple Myeloma
Recent Videos
Navigating Treatment Choices in R/R FL: Patient Values and Shared Decision-Making
Assessing CAR T and Bispecifics for R/R FL: Identifying the Right Candidates & Factoring in CD20 and CD19 Negativity or Positivity
Managing Epithelioid Sarcoma: Follow-Up Strategies and Treatment Decisions for Stable Disease vs Progression
Navigating Frontline Therapy in Epithelioid Sarcoma: Key Clinical Considerations and Shared Decision-Making
Optimizing Multidisciplinary Coordination for Successful Tarlatamab Implementation
Institutional Implementation: Setting Up Tarlatamab Administration
Clinician Experiences: COCOON Regimen vs Traditional SoC AE Management
Initial Reactions to COCOON Study’s Dermatologic/Nail AE Reductions
Choosing Between Tazemetostat and Zanubrutinib+Obinutuzumab: Key Factors & Patient Conversations
Research Considerations for ctDNA Testing in Colorectal Cancer
